BioLineRx Ltd.
BLRX
$4.24
-$0.33-7.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 93.09% | 84.79% | 62.03% | 30.42% | -52.71% |
| Total Depreciation and Amortization | 66.07% | 201.28% | 230.64% | 181.18% | 165.27% |
| Total Amortization of Deferred Charges | 2,347.46% | 1,157.63% | -- | -65.50% | -65.50% |
| Total Other Non-Cash Items | -254.88% | -182.01% | -139.68% | -104.02% | 1,029.77% |
| Change in Net Operating Assets | -378.18% | -243.55% | -481.66% | -394.12% | 210.38% |
| Cash from Operations | -12.73% | -94.06% | 9.04% | 5.35% | -0.11% |
| Capital Expenditure | 81.90% | 54.31% | 52.23% | 54.76% | 20.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.96% | 1,786.35% | -108.13% | -219.64% | 102.00% |
| Cash from Investing | -60.75% | 1,934.21% | -108.47% | -223.80% | 105.16% |
| Total Debt Issued | -- | -- | 3,557.37% | 110.64% | -- |
| Total Debt Repaid | -439.96% | -651.71% | -203.86% | -170.26% | -31.28% |
| Issuance of Common Stock | 59.92% | -2.85% | 308.82% | 60.39% | 18.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 118.15% | 37.21% | 1,155.41% | 74.64% | -33.38% |
| Foreign Exchange rate Adjustments | -48.00% | 109.82% | 111.16% | 74.04% | 88.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 199.02% | 197.62% | 120.62% | 87.65% | -29.24% |